In Silico Design of a Chimeric Humanized L-asparaginase
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087550 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Alejandro Pedroso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Faculty of Engineering and Science, Universidad de La Frontera, Temuco 4811230, Chile. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation, Production of extracelular L-asparaginase: from bioprospecting to the engineering of an antileukemic biopharmaceutical.
Abstract (Originalsprache)
Acute lymphoblastic leukemia (ALL) is the most common cancer among children worldwide, characterized by an overproduction of undifferentiated lymphoblasts in the bone marrow. The treatment of choice for this disease is the enzyme L-asparaginase (ASNase) from bacterial sources. ASNase hydrolyzes circulating L-asparagine in plasma, leading to starvation of leukemic cells. The ASNase formulations of E. coli and E. chrysanthemi present notorious adverse effects, especially the immunogenicity they generate, which undermine both their effectiveness as drugs and patient safety. In this study, we developed a humanized chimeric enzyme from E. coli L-asparaginase which would reduce the immunological problems associated with current L-asparaginase therapy. For these, the immunogenic epitopes of E. coli L-asparaginase (PDB: 3ECA) were determined and replaced with those of the less immunogenic Homo sapiens asparaginase (PDB:4O0H). The structures were modeled using the Pymol software and the chimeric enzyme was modeled using the SWISS-MODEL service. A humanized chimeric enzyme with four subunits similar to the template structure was obtained, and the presence of asparaginase enzymatic activity was predicted by protein–ligand docking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, Faculty of Engineering and Science, Universidad de La Frontera, Temuco 4811230, Chile.
- Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Avenida Carlos Schorr 255, Talca 3460000, Chile.
- Department of Internal Medicine, East Division, Faculty of Medicine, University of Chile, Santiago 7500922, Chile.
- Department of Biochemical and Pharmaceutical Technology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
- Department of Family Medicine, Faculty of Medicine, University of Medical Sciences Matanzas, Matanzas 42300, Cuba.
ORCID-Profile: Adalberto Pessoa, Jorge G Farías
Förderung
- São Paulo Research Foundation
- Production of extracelular L-asparaginase: from bioprospecting to the engineering of an antileukemic biopharmaceutical
Zitieren
APA
Pedroso, A., Herrera Belén, L., Beltrán, J. F., Castillo, R. L., Pessoa, A., Pedroso, E., & Farías, J. G. (2023). In Silico Design of a Chimeric Humanized L-asparaginase. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087550
Vancouver
Pedroso A, Herrera Belén L, Beltrán JF, Castillo RL, Pessoa A, Pedroso E, et al. In Silico Design of a Chimeric Humanized L-asparaginase. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087550
BibTeX
@article{Pedroso2023,
author = {Pedroso, Alejandro and Herrera Belén, Lisandra and Beltrán, Jorge F and Castillo, Rodrigo L and Pessoa, Adalberto and Pedroso, Enrique and Farías, Jorge G},
title = {In Silico Design of a Chimeric Humanized L-asparaginase},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087550}
}
EUVIMED